This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.
Ectopic pregnancy is considered a life-threatening condition which requires immediate intervention. Owing to the advancements in medical technology, ectopic pregnancy can now be diagnosed in the early stages. Methotrexate (MTX) is an antimetabolite drug showing a competitive reversible binding concerning natural dihydrofolates and acting as an inhibitor of the dihydrofolate-reductase (DHFR), a key enzyme synthesizing the tetrahydrofolates needed for the synthesis of purine and pyrimidine rings.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
34
Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
Tanta University
Tanta, El-Gharbia, Egypt
RECRUITINGTime for serum b-hCG remission
Time for serum b-hCG remission will be recorded to be less than 20 iu/ml.
Time frame: Post intervention for 3 months
Success rate
Success rate will be recorded.
Time frame: Post intervention for 3 months
Time for uterine-mass disappearance
Time for uterine-mass disappearance will be recorded.
Time frame: Post intervention for 3 months
Hospitalization time
Hospitalization time will be recorded from admission till discharge from hospital.
Time frame: 15 days after intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.